# An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

> **NCT03845712** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UCB BIOSCIENCES, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Thymidine Kinase 2 Deficiency

## Interventions

- **DRUG:** doxecitine and doxribtimine

## Key facts

- **NCT ID:** NCT03845712
- **Lead sponsor:** UCB BIOSCIENCES, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-05
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03845712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03845712, "An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03845712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*